2017 overtakes the already significant 2016 result by 13% for ASAlaser, whose key pillars consist in research, internationalisation and training. In order to reach this objective, the company has also increased its staff by 20% and further increases are forecast during the year. “People represent a primary asset for us – explains Roberto Marchesini, CEO of ASAlaser – this is why investing in internal staff training is mandatory for us”. This is also confirmed by the figures: more than 2000 hours of training were provided during 2017, structured in group and one-to-one courses.
Finally, funds for Research also ensure continuity: in 2016 the Company allocated approximately 13.5% of the turnover, which was increased to 14% in 2017. “To date, there are more than 150 scientific studies in the fields of research and clinical trials promoted by ASA. On average every year – explains Lucio Zaghetto, the Scientific & Educational Director – there are 6/7 basic and clinical research programmes, with an average length of 2-3 years, conducted directly by ASAcampus staff (the ASAlaser research division, ed.) and the same commitment is also scheduled for this year”. For the company, a year which will be in the name of the recognition of the innovative TT therapeutic strategy and of the HIRO TT device – successfully presented at “MEDICA 2017- World Forum for medicine” – and of the development of further therapeutic solutions. “2018 – previews Marchesini – will also be the year during which we will lay the foundations of the new production site, suitable for ensuring the best quality of work to all our employees”.